Moreover, B-CLL cells acquire the capacity to evade the immune response, taking advantage of immune checkpoint pathways due to increased levels of inhibitory proteins such as PD-1, PD-L1, CTLA-4, TIM-3, LAG-3, and CD47, and are responsible for modulating the activity of T and NK cells by playing a negative role in their activation. This evidence concerns the gene LAG3 and B-cell chronic lymphocytic leukemia.